FDA Inspection 1230852 — Byoung Chul Cho, M.D., Ph.D.
The FDA completed an inspection of Byoung Chul Cho, M.D., Ph.D. on February 2, 2024 in Seodaemun. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 2, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Seodaemun (Korea (the Republic of))
Additional Details
Clinical Investigator (CI)